Inactive Instrument

PCAS

PCA

FR0000053514

PCAS SA Reports Sales Results for the Year Ended December 31, 2020

January 28, 2021 at 11:20 pm IST

PCAS SA reported sales results for the year ended December 31, 2020. For the period, the company reported net sales of EUR 194.1 million against EUR 200.9 million a year ago.

Latest news about PCAS

Orapi: takeover bid reopens on February 12	09/02	CF
Orapi: 3.15 million shares tendered to the takeover bid	02/02	CF
Orapi: takeover bid opens on December 27	22/12	CF
PCAS: 200 ME capital increase	18/12	CF
PCAS: OPAS to start this Friday	03/11	CF
PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	24/23/24	CI
Progyny, Inc. : Want to have a baby?	16/23/16
PCAS: Seqens launches minority share offer	07/23/07	CF
PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	06/23/06	CI
PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	27/23/27	CI
DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	01/23/01	CI
PCAS: sale of Canadian subsidiary confirmed	25/23/25	CF
PCAS to Divest Canadian Arm to Japan's DIC	25/23/25	MT
DIC Corporation agreed to acquire PCAS Canada Inc. from PCAS SA for an enterprise value of ?88.2 million.	25/23/25	CI
PCAS in Talks to Sell Canada Unit to DIC	09/23/09	CI
PCAS: buoyed by offer for Canadian subsidiary	03/23/03	CF
France's PCAS Enters Exclusive Talks for Canadian Unit Sale to Japan's DIC	03/23/03	MT
PCAS: larger net loss in 2022	31/23/31	CF
Global markets live: Airbus, Manchester United, EA, Credit Suisse, Warner...	30/23/30
PCAS SA Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
PCAS: 21% increase in sales by 2022	07/23/07	CF
PCAS SA Reports Consolidated Net Sales Results as of December 31, 2022	07/23/07	CI
PCAS CEO Resigns; Acting Successor Named	29/22/29	MT
Pcas Sa Announces Executive Changes	28/22/28	CI
Pcas Appoints Mr. Jean-Louis Martin as Director	28/22/28	CI

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr

Other Pharmaceuticals

PCAS

Equities

PCA

FR0000053514

Pharmaceuticals

PCAS SA Reports Sales Results for the Year Ended December 31, 2020

Latest news about PCAS

Chart PCAS

Company Profile

Sector Other Pharmaceuticals